Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells

Oncogene

Volumn 26, Issue 17, 2007, Pages 2459-2470

  Mangala, L S ^a   Fok, J Y ^a   Zorrilla Calancha, I R ^a   Verma, A ^a   Mehta, K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cell migration; Fibronectin; Integrins; Invasion; Metastasis; Transglutaminase

Indexed keywords

BETA1 INTEGRIN; BETA4 INTEGRIN; BETA5 INTEGRIN; FIBRONECTIN; PACLITAXEL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CELL ADHESION; CELL INVASION; CELL MOTILITY; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; NEOPLASM INVASIVENESS; PHENOTYPE; TRANSGLUTAMINASES;

EID: 34247153086     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210035     Document Type: Article

References (47)

1. Aeschlimann D, Thomazy V. (2000). Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 41: 1-27.
2. Akimov SS, Belkin AM. (2001). Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFβ-dependent matrix deposition. J Cell Sci 114: 2989-3000.
3. Aoudjit F, Vuori K. (2001). Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20: 4995-5004.
4. Baek KJ, Kang S, Damron D, Im M. (2001). Phospholipase Cdelta1 is a guanine nucleotide exchanging factor for transglutaminase II (Galpha h) and promotes alpha 1B-adrenoreceptor-mediated GTP binding and intracellular calcium release. J Biol Chem 276: 5591-5597.
5. Balklava Z, Verderio E, Collighan R, Gross S, Adams J, Griffin M. (2002). Analysis of tissue transglutaminase in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but it is important for its secretion. J Biol Chem 277: 16567-16575.
6. Belkin AM, Tsurupa G, Zemskov E, Veklich Y, Weisel JW, Medved L. (2005). Transglutaminase-mediated oligomerization of the fibrin(ogen) alphaC domains promotes integrin-dependent cell adhesion and signaling. Blood 105: 3561-3568.
7. Chandrashekar R, Tsuji N, Morales T, Ozols V, Mehta K. (1998). Cloning of a novel transglutaminase from dog heart worm with protein disulfide isomerase activity. Proc Natl Acad Sci USA 95: 531-536.
8. Chen J, Kanopleva M, Multani A, Pathak S, Mehta K. (2004). Drug resistant breast cancer MCF-7 cells are paradoxically sensitive to apoptosis. J Cell Physiol 200: 223-234.
9. Chen JS, Agarwal N, Mehta K. (2002). Multidrug-resistant MCF-7 breast carcinoma cells contain deficient intracellular calcium pools. Br Cancer Res Treat 71: 237-247.
10. Chen JS, Mehta K. (1999). Tissue transglutaminase: an enzyme with a split personality. Int J Biochem Cell Biol 31: 817-836.
11. Cordes N, Blaese MA, Plasswilm L, Rodemann HP, Van Beuningen D. (2003). Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells in vitro. Int J Radiat Biol 79: 709-720.
12. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. (1999). Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658-1667.
13. Damiano JS, Hazlehurst LA, Dalton WS. (2001). Cell adhesion mediated drug resistance protects K562 cells from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15: 1232-1239.
14. Fesus L, Piacentini M. (2002). Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27: 534-539.
15. Han JA, Park SC. (1999). Reduction of transglutaminase-2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 125: 89-95.
16. Hang J, Zemskov EA, Lorand L, Belkin AM. (2005). Identification of a novel recognition sequence for fibronectin within the NH2-terminal b-sandwich domain of tissue transglutaminase. J Biol Chem 280: 23675-23683.
17. Herman JF, Mangala LS, Mehta K. (2006). Implications of increased tissue transglutaminase expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25: 3049-3058.
18. Janiak A, Zemskov E, Belkin AM. (2006). Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway. Mol Biol Cell 17: 1606-1619.
19. Jeong JM, Murthy SN, Radek JT, Lorand L. (1995). The fibronectin-binding domain of transglutaminase. J Biol Chem 270: 5654-5658.
20. Jiang D, Ying W, Lu Y, Wan J, Zhai Y, Liu W et al. (2003a). Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 3: 724-737.
21. Jiang WG, Ablin R, Douglas-Jones A, Mansel RE. (2003b). Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol Rep 10: 2039-2044.
22. Joshi S, Guleria R, Pan J, DiPette D, Singh US. (2006). Retinoic acid receptors and tissue tansglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 25: 240-247.
23. Korah R, Boots M, Wieder R. (2004). Integrin α5β1 promotes survival of growth arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 64: 4514-4522.
24. Leroy P, Berto F, Bourget I, Rossi B. (2004). Down-regulation of Hox A7 is required for cell adhesion and migration on fibronectin during early HL-60 monocytic differentiation. J Leukocyte Biol 75: 680-688.
25. Lipscomb EA, Mercurio AM. (2005). Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metast Rev 24: 413-423.
26. Longtin R. (2004). Birthday of a breakthrough: fibronectin research proves important, but not as originally expected. J Natl Cancer Inst 96: 6-8.
27. Lorand L, Graham RM. (2003). Transglutaminases: cross-linking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4: 140-156.
28. Mauro L, Sisci D, Bartucci M, Salerno M, Kim J, Tam T et al. (1999). SHC-alpha5beta1 integrin interactions regulate breast cancer cell adhesion and motility. Exp Cell Res 252: 439-448.
29. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. (2005). The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5: 505-515.
30. Mehlen P, Puisieux A. (2006). Metastasis: a question of life or death. Nat Rev Cancer 6: 449-458.
31. Mehta K. (2005). Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 38: 1-18.
32. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. (2004). Prognostic significance of tissue transglutaminase expression in drug-resistant and metastatic breast cancer. Clin Cancer Res 10: 8068-8076.
33. Milakovic T, Tucholski J, McCoy E, Johnson JVW. (2004). Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 279: 8715-8722.
34. Mishra S, Murphy LJ. (2004). Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 279: 23863-23868.
35. Mishra S, Murphy LJ. (2006). The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 339: 726-730.
36. Mishra S, Saleh A, Espino PS, Davie JR, Murphy LJ. (2006). Phosphorylation of histones by tissue transglutaminase. J Biol Chem 281: 5532-5538.
37. Mohan K, Pinto D, Issekutz TB. (2003). Identification of tissue transglutaminase as a novel molecule involved in human CD8+ cell transendothelial migration. J Immunol 171: 3179-3186.
38. Parise LV, Lee J, Juliano RL. (2000). New aspects of integrin signaling in cancer. Semin Cancer Biol 10: 407-414.
39. Parker B, Sukumar S. (2003). Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biol Ther 2: 14-21.
40. Price LS, Leng J, Schwartz MA, Bokoch GM. (1998). Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol Biol Cell 9: 1863-1871.
41. Priglinger SG, Alge CS, Neubauer AS, Kristen N, Hirneiss C, Eibl K et al. (2004). TGF-beta2-induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain. Invest Ophthalmol Vis Sci 45: 955-963.
42. Singh US, Kunar MT, Kao YL, Baker KM. (2001). Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase. EMBO J 20: 2413-2423.
43. Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T. (2000). Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 275: 16309-16315.
44. Verderio E, Nicholas B, Gross S, Griffin M. (1998). Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of fibronectin, cell attachment, and cell death. Exp Cell Res 239: 119-138.
45. Yoneda T. (2000). Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 5: 75-81.
46. Zemskov EA, Janiak A, Hang J, Waghray A, Belkin AM. (2006). The role of tissue transglutaminase in cell-matrix interactions. Front Biosci 11: 1057-1076.
47. Zhang Z, Vuori K, Reed JC, Ruoslahti E. (1995). The alpha5 beta1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92: 6161-6165.